<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03432468</url>
  </required_header>
  <id_info>
    <org_study_id>LanZhouU</org_study_id>
    <nct_id>NCT03432468</nct_id>
  </id_info>
  <brief_title>Effect of Fully Blocking Type 1 Angiotensin Receptor on Target Organ Damage of Postmenopausal Hypertensive Women</brief_title>
  <official_title>Effect of Fully Blocking Type 1 Angiotensin Receptor on Blood Pressure, Cardiac Structure, Cardiac Function and Cognitive Function in Postmenopausal Hypertensive Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LanZhou University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LanZhou University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compared the improvements of blood pressure levels, left ventricular hypertrophy,
      left ventricular diastolic function, vascular function and cognitive function between
      postmenopausal hypertensive women and age-matched hypertensive male patients through the
      evaluation of the effects of fully blocked AT1 receptor by valsartan. Additionally, the
      differences of the above indexes between the patients who were fully blocked AT1 receptor by
      valsartan and the patients who were treated with a single dose of valsartan treatment were
      assessed, so as to provide theory basis for clinical treatment of postmenopausal hypertensive
      women.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2018</start_date>
  <completion_date type="Anticipated">August 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative indexes of myocardial remodeling</measure>
    <time_frame>Change from Baseline left ventricular mass index at 6 months.</time_frame>
    <description>Cardiac structure (left ventricular mass index in grams for square meter) measurement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative indexes of myocardial remodeling</measure>
    <time_frame>Change from Baseline left ventricular mass index at 12 months.</time_frame>
    <description>Cardiac structure (left ventricular mass index in grams for square meter) measurement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ambulatory blood pressure monitoring</measure>
    <time_frame>Change from Baseline ABPM at 6 months.</time_frame>
    <description>Non-invasive ambulatory blood pressure monitoring (ABPM) was performed for every enrolled patient with an ABPM equipment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ambulatory blood pressure monitoring</measure>
    <time_frame>Change from Baseline ABPM at 12 months.</time_frame>
    <description>Non-invasive ambulatory blood pressure monitoring (ABPM) was performed for every enrolled patient with an ABPM equipment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sexual hormones</measure>
    <time_frame>Baseline sexual hormones.</time_frame>
    <description>Blood samples used to analyze the levels of sexual hormones were collected between morning 8:00 and 9:00 after an overnight fast. The sexual hormones which include prolactin (PRL) and progesterone (P) units on nanogram per millilitre, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) units on millionInternationalUnits per millilitre, testosterone (T) in nanogram per deciliter, estradiol (E2) in picogram per millilitre.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>postmenopausal hypertensive women</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>age-matched hypertensive male patients</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan 1</intervention_name>
    <description>the high dose of valsartan</description>
    <arm_group_label>postmenopausal hypertensive women</arm_group_label>
    <arm_group_label>age-matched hypertensive male patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan 80 mg</intervention_name>
    <description>a single dose of valsartan</description>
    <arm_group_label>postmenopausal hypertensive women</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of hypertension

          -  Women are all postmenopausal

          -  Must provide written informed consent

        Exclusion Criteria:

          -  Secondary hypertension

          -  Coronary disease

          -  Heart failure

          -  Arterial fibrillation

          -  Previous myocardial infarction

          -  Previous stroke

          -  Malignant disease

          -  Kidney failure

          -  Liver failure

          -  Neoplastic disease

          -  Severe neurological diseases

          -  Severe metabolic or organic decompensation

          -  Refuse to sign the informed consent form
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2018</study_first_submitted>
  <study_first_submitted_qc>February 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2018</study_first_posted>
  <last_update_submitted>March 10, 2018</last_update_submitted>
  <last_update_submitted_qc>March 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>LanZhou University</investigator_affiliation>
    <investigator_full_name>Jing Yu</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Left Ventricular Hypertrophy</keyword>
  <keyword>Women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

